FDA Accepts REGEN-COV® (casirivimab and imdevimab) for

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority...

Related Keywords

Japan , United States , India , United Kingdom , Brazil , South Africa , Colombia , Canada , Switzerland , September Regeneron , Georged Yancopoulos , Tammy Allen , Regeneron Velocimmune , Vesna Tosic , Twitter , Human Service Office Of The , Regeneron Velocimmune Technology , Nasdaq , Teva Pharmaceutical Industries Ltd , Department Of Health , European Union , Pharmaceuticals Inc , Centers For Disease , Regeneron Pharmaceuticals Inc , Biomedical Advanced Research , Regeneron Genetics Center , Human Services , Us Department Of Health , Drug Administration , Development Authority , Exchange Commission , European Medicines Agency , National Infusion Center Association , Biologics License Application , Marketing Authorization Application , Emergency Use Authorization , National Infusion Center , Human Service Office , Assistant Secretary , Fact Sheet , Chief Scientific Officer George , Authorized Use , Exposure Prophylaxis , Disease Control , Post Exposure Prophylaxis , Healthcare Providers , Dear Healthcare Provider Letter , Patient Fact , Identifying High Risk , Antiviral Resistance , Including Anaphylaxis , Infusion Related Reactions , Subcutaneous Dosing , Monitoring Recommendations , Specific Populations , Looking Statements , Regeneron Pharmaceuticals , Product Candidates , Biologics License Applications , Marketing Authorization Applications , Teva Pharmaceutical Industries , Nc ,